In a report released yesterday, Eun Yang from Jefferies maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report), with a price target of $22.00. The company’s shares closed yesterday at $14.95.
According to TipRanks, Yang is a 4-star analyst with an average return of 3.8% and a 48.99% success rate. Yang covers the Healthcare sector, focusing on stocks such as CureVac, United Therapeutics, and Wave Life Sciences.
Aerovate Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.00.
See the top stocks recommended by analysts >>
Based on Aerovate Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $16.52 million. In comparison, last year the company had a GAAP net loss of $11.5 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Read More on AVTE:
